---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-022001"
form_type: "8-K"
ticker: "LTRN"
cik: "0001763950"
company_name: "Lantern Pharma Inc."
filed_at: "2023-06-21T23:59:59+00:00"
generated_at: "2026-06-13T20:10:11.980419+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Lantern Pharma shareholders elect directors, approve 250K share increase, ratify auditor

## Summary
- All six director nominees elected: Donald Jeff Keyser, Panna Sharma, Vijay Chandru, Maria Maccecchini, Franklyn Prendergast, David S. Silberstein.
- Amendment to 2018 Equity Incentive Plan approved to increase shares available by 250,000; votes: 4,145,520 For, 96,840 Against, 14,138 Abstain.
- Ratification of EisnerAmper LLP as independent auditor for FY 2023 approved with 7,015,460 For, 41,115 Against, 5,164 Abstain.

## SEC filing metadata
- accession: 0001493152-23-022001
- form_type: 8-K
- ticker: LTRN
- cik: 0001763950
- company_name: Lantern Pharma Inc.
- filed_at: 2023-06-21T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1763950/000149315223022001/0001493152-23-022001-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1763950/000149315223022001/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-022001
- JSON: https://secwatch.observer/filing/0001493152-23-022001.json
- Plain text: https://secwatch.observer/filing/0001493152-23-022001.txt

## Key facts
- Shareholder Votes
  Lantern Pharma Inc. shareholders approved Election of six directors to serve until the 2024 Annual Meeting of Stockholders at the 2023-06-16 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-16
  source text: Election of Directors : All of the persons nominated to serve on our board of directors, namely Donald Jeff Keyser, Panna Sharma, Vijay Chandru, Maria Maccecchini, Franklyn Prendergast, and David S. Silberstein, were elected to our board of directors, with shares voted as follows: Name For Withheld Broker Non-Vote Donald Jeff Keyser 3,812,521 443,977 2,805,241 Panna Sharma 4,064,225 192,273 2,805,241 Vijay Chandru 3,810,172 446,326 2,805,241 Maria Maccecchini 3,811,686 444,812 2,805,241 Franklyn Prendergast 4,048,745 207,753 2,805,241 David S. Silberstein 4,060,996 195,502 2,805,241
  evidence_url: https://www.sec.gov/Archives/edgar/data/1763950/000149315223022001/0001493152-23-022001-index.htm
- Shareholder Votes
  Lantern Pharma Inc. shareholders approved Ratification of the appointment of EisnerAmper LLP as independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-16 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-16
  source text: Ratification of Independent Registered Public Accounting Firm : In addition, our stockholders ratified the appointment of EisnerAmper LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023, with shares voted as follows: For 7,015,460 Against 41,115 Abstain 5,164 There were no broker non-votes on the ratification of our independent registered public accounting firm.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1763950/000149315223022001/0001493152-23-022001-index.htm
- Shareholder Votes
  Lantern Pharma Inc. shareholders approved Approval of an amendment to the Second Amended and Restated Lantern Pharma Inc. 2018 Equity Incentive Plan to increase the number of shares available for issuance by an additional 250,000 shares at the 2023-06-16 meeting.
  - Proposal: equity plan
  - Outcome: passed
  - Meeting: 2023-06-16
  source text: Amendment to Equity Incentive Plan : Our stockholders approved an amendment to the Equity Incentive Plan to increase the number of shares of the Company’s common stock available for issuance under the Equity Incentive Plan by an additional 250,000 shares, with shares voted as follows: For 4,145,520 Against 96,840 Abstain 14,138 Broker Non-Votes 2,805,241
  evidence_url: https://www.sec.gov/Archives/edgar/data/1763950/000149315223022001/0001493152-23-022001-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.